Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Erythrocyte membrane transporter regulation" is not a specific molecule or receptor but rather refers to the collective regulation of multiple **membrane transport proteins** present on the surface of red blood cells. The most prominent among these is **band 3** (*anion exchanger 1*, gene symbol *SLC4A1*), which mediates chloride/bicarbonate exchange critical for CO₂ carriage and acid-base balance. Other major erythrocyte membrane transporters include **GLUT1** (*SLC2A1*, glucose uniporter), **aquaporin 1** (water channel), urea transporter (*Kidd antigen*), and RhAG (*gas channel*). These proteins are essential for maintaining erythrocyte function, including gas exchange, metabolic support, osmotic balance, cell shape integrity, and mechanical resilience during circulation. Defects in these individual proteins can lead to various hereditary hemolytic anemias or altered red cell physiology. However, "erythrocyte membrane transporter regulation" as a phrase does not denote a single molecular target but rather encompasses a set of processes involving several distinct molecules with different functions. Because this entry refers to a regulatory process involving multiple targets—not one specific molecule—it should be flagged as incorrect if used as a canonical therapeutic target name. > "Erythrocytes are endowed with functional entities that support either cellular functions or the systemic delivery of O₂ from lung to tissue... associated... with cytosolic haemoglobin and the major membrane polypeptide band 3..." [Band 3] "...mediates Cl⁻/HCO₃⁻ exchange..." [Other] "...major membrane transporters are apparently essential for maintaining stable erythrocyte cell shape..." > "Membrane proteins with transport function include band 3 (anion transporter), aquaporin 1 (water transporter), Glut1... Kidd antigen protein..., RhAG..." [These] "...link bilayer to skeleton through their interactions with skeletal proteins..." In summary: This term describes a group regulatory concept rather than one discrete druggable entity; it should be replaced by more precise names such as "Anion exchanger 1" ("Band 3", SLC4A1) when referring to specific targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Erythrocyte membrane transporter.